Updated boosters from Pfizer/BioNTech and Moderna were made available earlier this month, shortly after FDA approval. However, some pharmacy chains have reported problems keeping Moderna’s shots in stock.
“The government’s supply of the updated Moderna COVID-19 booster is currently limited, causing product appointments to vary across the country,” Walgreens said Tuesday. “Updated Pfizer COVID-19 booster remains available”.
Rite Aid said Tuesday: “We have received a limited supply of Moderna COVID-19 boosters and expect to receive additional supplies in the coming weeks. We are actively working to increase our inventory of COVID boosters and have sufficient supplies of updated Pfizer boosters in all stores.”
FDA spokesman Michael Felberbaum said Tuesday that when the agency authorized the updated boosters, it was in the middle of an inspection of a facility where Moderna’s boosters are made, so “FDA did not include this facility as an authorized manufacturing facility for the updated COVID-19 vaccine booster at the time.” in that”. Only Moderna lots from another facility were available at that time.
But on Tuesday, the agency said it had determined that “multiple batches” of the Moderna booster made at the first facility met criteria for distribution, “after carefully reviewing the information provided by Moderna regarding the manufacturing of these batches. The agency has no concerns about the safety, efficacy or quality of these batches.” ” said Felberbaum.
Moderna said it is still on track to deliver 70 million doses of its updated vaccine by the end of 2022.
“We are working closely with the US Government to provide significant quantities of updated, bivalent booster doses as we continue to see high demand in certain areas of the country,” the company said. “We anticipate that these availability limitations will be resolved in the coming days.”
The use of Covid-19 vaccine boosters was low before updated boosters became available. So far, less than half of the people in the U.S. who received the initial series and are eligible for a booster — and less than a third of the population — received the booster.